MedTrace Logo

Chicago Social Drinking Project

NCT00961792 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2026-04-09

No results posted yet for this study

Summary

This study attempts to elucidate the factors that contribute to escalation and maintenance of excessive ethanol drinking in young adults by:

1. Examining subjective and objective response differences to alcohol and other common substances in a sample of adults with varying consumption patterns.
2. Determining whether response to alcohol and other substances is predictive of future consumption patterns through longitudinal follow-up interviews.
3. Examining the relationship between responses to alcohol and other substances at baseline and re-examination testing to evaluate if consumption patterns moderate this relationship.

Conditions

  • Alcoholism

Interventions

DRUG

Ethanol

Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol

DRUG

Placebo

Beverage containing 0.0 g/kg alcohol to act as placebo

DRUG

Diphenhydramine

Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)

DRUG

Caffeine

Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • University of Chicago

    lead OTHER

Principal Investigators

  • Andrea C King, PhD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2026-09-30
Completion
2027-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00961792 on ClinicalTrials.gov